Clinicopathologic characteristics and treatment outcome of patients
| Patient . | Sex/age . | Karyotype . | Previous treatment . | BBMR (d) . | TTP . | FLT3 ITD(%) . | D835 mutant (%) . | ||
|---|---|---|---|---|---|---|---|---|---|
| Before . | Progress . | Before . | Progress . | ||||||
| 1 | F/59 | Normal | 7 + 3; 5 + 2 × 2 | nCRi (27) | 68 | 44 | 40 | 0 | 46 |
| 2 | F/36 | Normal | 7 + 3; ICE; MZ/AC; FLAG-IDA | CRi (21) | 54 | 98 | NA | ND | NA |
| 3 | F/21 | Normal | 7 + 3; ICE × 2 MUD BMT | nCRi (22) | 61 | 41 | 33 | 0 | 0 |
| 4 | F/69 | Normal | MZ/Eto | CRi (21) | 86 | 75 | 94 | 0 | 68 |
| 5 | F/51 | Normal | 7 + 3; ICE × 2 | CRi (65) | 287 | 86 | NA | ND | NA |
| 6 | M/53 | t(6;9)* | 7 + 3; ICE; HDAC | CRi (23) | Sib BMT on day 38 at Cri§ | 67 | NA | ND | NA |
| 7 | F/43 | Normal† | 7 + 3; 5 + 2 × 2; MZ/AC/Eto; MZ/AC | nCRi (21) | 92 | 33 | 42 | 0 | 0 |
| 8 | F/47 | Normal | 7 + 3; ICE × 3 | nCRi (84) | 99 | 39 | 40 | 3 | 37 |
| 9 | F/41 | Normal | 7 + 3; 5 + 2; HDAC × 4; MUD BMT | NR | NA | 28 | NA | ND | NA |
| 10 | M/50 | Normal | 7 + 3; 5 + 2 × 2; HDAC × 3 ICE; CLO/AC | nCRi (27) | 72 | 44 | 40 | 0 | 58 |
| 11 | F/47 | Normal | 7 + 3; ICE × 2 | CRi (33) | In CRi after 60 days‖ | 100 | 100 | 0 | 66 |
| 12 | F/13 | Normal | NOPHO-AML; FLAG; MZ/AC; UCBT | CRi (42) | HT on day 58 at Cri§ | 30 | NA | 0 | 0 |
| 13‡ | F/57 | Normal | 7 + 3; ICE; Sib BMT | Not defined | 63 | 38 | NA | ND | NA |
| Patient . | Sex/age . | Karyotype . | Previous treatment . | BBMR (d) . | TTP . | FLT3 ITD(%) . | D835 mutant (%) . | ||
|---|---|---|---|---|---|---|---|---|---|
| Before . | Progress . | Before . | Progress . | ||||||
| 1 | F/59 | Normal | 7 + 3; 5 + 2 × 2 | nCRi (27) | 68 | 44 | 40 | 0 | 46 |
| 2 | F/36 | Normal | 7 + 3; ICE; MZ/AC; FLAG-IDA | CRi (21) | 54 | 98 | NA | ND | NA |
| 3 | F/21 | Normal | 7 + 3; ICE × 2 MUD BMT | nCRi (22) | 61 | 41 | 33 | 0 | 0 |
| 4 | F/69 | Normal | MZ/Eto | CRi (21) | 86 | 75 | 94 | 0 | 68 |
| 5 | F/51 | Normal | 7 + 3; ICE × 2 | CRi (65) | 287 | 86 | NA | ND | NA |
| 6 | M/53 | t(6;9)* | 7 + 3; ICE; HDAC | CRi (23) | Sib BMT on day 38 at Cri§ | 67 | NA | ND | NA |
| 7 | F/43 | Normal† | 7 + 3; 5 + 2 × 2; MZ/AC/Eto; MZ/AC | nCRi (21) | 92 | 33 | 42 | 0 | 0 |
| 8 | F/47 | Normal | 7 + 3; ICE × 3 | nCRi (84) | 99 | 39 | 40 | 3 | 37 |
| 9 | F/41 | Normal | 7 + 3; 5 + 2; HDAC × 4; MUD BMT | NR | NA | 28 | NA | ND | NA |
| 10 | M/50 | Normal | 7 + 3; 5 + 2 × 2; HDAC × 3 ICE; CLO/AC | nCRi (27) | 72 | 44 | 40 | 0 | 58 |
| 11 | F/47 | Normal | 7 + 3; ICE × 2 | CRi (33) | In CRi after 60 days‖ | 100 | 100 | 0 | 66 |
| 12 | F/13 | Normal | NOPHO-AML; FLAG; MZ/AC; UCBT | CRi (42) | HT on day 58 at Cri§ | 30 | NA | 0 | 0 |
| 13‡ | F/57 | Normal | 7 + 3; ICE; Sib BMT | Not defined | 63 | 38 | NA | ND | NA |
BBMR indicates best bone marrow response; TTP, time to progression; 7 + 3, daunorubicin (3 days) and cytarabine (7 days); 5 + 2, daunorubicin (2 days) and cytarabine (5 days); ICE, idarubicin, cytarabine and etoposide; MZ/AC, mitoxantrone and cytarabine; FLAG-IDA, fludarabine, cytarabine, G-CSF, idarubicin; MUD, matched unrelated donor; BMT, bone marrow transplantation; MZ, mitoxantrone; Eto, etoposide; AC, cytarabine; HDAC, high dose cytarabine; CLO, clofarabine; nCRi, near complete remission with insufficient hematological recovery; HT, haplotype identical transplantation; Before, before sorafenib treatment; Progress, leukemia progression after initial CRi/nCRi despite continuous sorafenib treatment; Sib, Sibling; NOPHO-AML, Nordic Society of Pediatric Hematology and Oncology Protocol; NA, not applicable; ND, not done; and NR, nonremission.
With trisomy 13.
Multiple karyotypic abnormalities at relapse.
Presented as right breast myeloid sarcoma at relapse.
CRi was confirmed by bone marrow biopsy before transplantation.
Continuous CRi at day 60 as indicated by the absence of circulating blasts.